MENLO PARK, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) (“CohBar” or the “Company”), an innovative
biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that its
abstract has been accepted for poster presentation at the upcoming American Diabetes Association 78th Scientific
Sessions in Orlando, Florida from June 22-26, 2018. During its Poster Session, the Company will present its findings to date about
the molecular mechanisms underlying CB4211’s efficacy in animal models of NASH.
Poster Presentation:
Title: CB4211 is a Potential Treatment for Metabolic Diseases with a Novel Mechanism of Action: Sensitization of the Insulin
Receptor
Category: 20-B Insulin Action: Cellular and Molecular Metabolism
Poster Session: Monday June 25, 2018, 12:00 PM – 1:00 PM EDT
Poster Number: 233-LB
Location: WA4-WB2
About CB4211
CB4211 is a first-in-class mitochondria based therapeutic that has demonstrated significant therapeutic potential in preclinical
models of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring
mitochondrial-derived peptide (MDP), which was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic
collaborators and has been shown to play a significant role in the regulation of metabolism. The Company expects CB4211 to enter a
Phase 1a/b clinical trial, which includes a potential activity readout relevant to NASH and obesity, in mid-2018.
About CohBar
CohBar is an innovative biotechnology company focused on the research and development of MBTs, an emerging class of drugs for
the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides encoded
within the mitochondrial genome called mitochondrial-derived peptides (MDPs), some of which have been shown to regulate metabolism
and cell death, and whose levels declined with age. CohBar’s efforts focus on the discovery of new MDPs, and their development into
novel MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction,
including nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases.
To date, the Company and its founders have discovered more than 100 MDPs.
For additional company information, please visit www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations for its lead
candidate program, including anticipated timing and results of its clinical trials, statements regarding the therapeutic potential
of these and other mitochondria based therapeutics. Forward-looking statements are based on current expectations, estimates and
projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those
anticipated by CohBar. These risks and uncertainties include, among other things, the uncertainties inherent in research and
development, including the ability to meet anticipated commencement and completion dates for initial clinical studies, as well as
the possibility of unfavorable study results, including unfavorable new data and additional analyses of existing data; risks
associated with initial data, including the risk that results of additional pre-clinical or clinical studies may be different from
(including less favorable than) the earlier data results and may not support further clinical development. Additional risks and
uncertainties include CohBar’s ability to retain key personnel, expand its research operations, and obtain financing necessary to
continue its operations and fund its candidate programs. Additional assumptions, risks and uncertainties are described in
detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable
Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ
materially from those set forth in the forward-looking statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to
buy any securities.
Investor and Media Contact:
Jon Stern, COO
CohBar, Inc.
(650) 446-7888
jon.stern@cohbar.com
